Humanigen, Inc. - Common Stock (NQ:HGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

October 26, 2021

From Humanigen, Inc.

Via Business Wire

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

October 25, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21

October 22, 2021

From Humanigen, Inc.

Via Business Wire

Expert Ratings For Humanigen ↗

September 10, 2021

Over the past 3 months, 4 analysts have published their opinion on Humanigen (NASDAQ:

Via Benzinga

Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors

October 20, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab

October 19, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients

October 11, 2021

From Humanigen, Inc.

Via Business Wire

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe

October 08, 2021

From Humanigen, Inc.

Via Business Wire

NASDAQ:HGEN Investor Notice: Investigation over Potential Securities Laws Violations by Humanigen, Inc. ↗

October 07, 2021

San Diego, CA -- (SBWIRE) -- 10/07/2021 -- An investigation was announced over potential securities laws violations by Humanigen, Inc. in connection with certain financial statements.

Via SBWire

Humanigen Announces Participation and Presentation at Multiple Conferences in October

October 04, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA

October 01, 2021

From Humanigen, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗

October 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

September 29, 2021

From Humanigen, Inc.

Via Business Wire

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab

September 28, 2021

From Humanigen, Inc.

Via Business Wire

Humanigen Announces Participation and Presentation at Multiple Conferences in September

September 14, 2021

From Humanigen, Inc.

Via Business Wire

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗

September 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...

Via Benzinga

60 Biggest Movers From Friday ↗

September 13, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...

Via Benzinga

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs ↗

September 12, 2021

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 10, 2021

Gainers Hepion Pharmaceuticals (NASDAQ:HEPA

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 10, 2021

Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million...

Via Benzinga

Why Humanigen Stock Is Sinking Today ↗

September 10, 2021

The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.

Via The Motley Fool

After FDA Rejection This Biopharma Stock Garners Analyst Downgrades, Price Cuts ↗

September 09, 2021

JPMorgan

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Gevo Shares Spike Higher ↗

September 09, 2021

Toward the end of trading Thursday, the Dow traded down 0.37% to 34,901.89 while the NASDAQ fell 0.03% to 15,281.73. The S&P also rose, gaining 0.31% to 4,499.94. The U.S. has...

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 ↗

September 10, 2021

Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE:

Via Benzinga

Stocks Inch Higher as Dow Looks to Snap Skid ↗

September 09, 2021

The Dow Jones Industrial Index is up 68 points midday and on track to snap a three-day losing streak.

Via Talk Markets

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 09, 2021

Gainers Impel NeuroPharma (NASDAQ:IMPL) shares increased by 22.16% to $20.29 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.1...

Via Benzinga

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗

September 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

48 Biggest Movers From Yesterday ↗

September 10, 2021

Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.